Antithymocyte globulin exposure in CD34 + T-cell-depleted allogeneic hematopoietic cell transplantation

Traditional weight-based dosing results in variable rabbit antithymocyte globulin (rATG) clearance that can delay CD41 T-cell immune reconstitution (CD41 IR) leading to highermortality. In a retrospective pharmacokinetic/pharmacodynamic (PK/PD) analysis of patients undergoing their first CD341 T-cell-depleted (TCD) allogeneic hematopoietic cell transplantation (HCT) after myeloablative conditioningwith rATG, we estimated post-HCT rATGexposure as area under the curve (arbitrary unit per day/milliliter [AU3day/mL]) using a validated population PKmodel. We related rATGexposure to nonrelapsemortality (NRM), CD4(+) IR (CD4(+) >= 50 cells per mu L at 2 consecutive measures within 100 days after HCT), overall survival, relapse, and acute graft-versus-host disease (aGVHD) to define an optimal rATG exposure. We used Cox proportional hazard models and multistate competing risk models for analysis. In all, 554 patients were included (age range, 0.1-73 years). Median post-HCT rATG exposure was 47 AU x day/mL (range, 0-101 AU x day/mL). Low post-HCT area under the curve (<30 AU x day/mL) was associated with lower risk of NRM (P < .01) and higher probability of achieving CD4(+) IR (P < .001). Patients who attained CD4(+) IR had a sevenfold lower 5-year NRM (P < .0001). The probability of achieving CD4(+) IR was 2.5-fold higher in the <30 AU x day/mL group compared with 30-55 AU x day/mL and threefold higher in the <30 AU x day/mL group compared with the >= 55 AU x day/mL group. In multivariable analyses, post-HCT rATG exposure >= 55 AU x day/mL was associated with an increased risk of NRM (hazard ratio, 3.42; 95% confidence interval, 1.26-9.30). In the malignancy subgroup (n = 515), a tenfold increased NRM was observed in the >= 55 AU x day/mL group, and a sevenfold increased NRM was observed in the 30-55 AU x day/mL group compared with the <30 AU x day/mL group. Post-HCT rATG exposure >= 55 AU x day/mL was associated with higher risk of a GVHD (hazard ratio, 2.28; 95% confidence interval, 1.01-5.16). High post-HCT rATG exposure is associated with higher NRM secondary to poor CD4(+) IR after TCD HCT. Using personalized PK-directed rATG dosing to achieve optimal exposure may improve survival after HCT.

Automated summary

The traditional weight-based dosing in rabbit antithymocyte globulin (rATG) treatment leads to variable clearance and higher mortality. A personalized pharmacokinetic-guided rATG dosing strategy can improve patient survival.